Leiden, The Netherlands, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that HansSchikan, Chief Executive Officer, will present a corporate overviewat the following investor conferences:
  • Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday,November 11, 2014 at 9:30am MST
  • Jefferies Global Healthcare Conference in London, UK onWednesday, November 19, 2014 at 4:20pm GMT

Live webcasts of the presentations can be accessed through theInvestors & Media section of the Prosensa corporate website at www.prosensa.com and will bearchived for 90 days.

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a biotechnology company engaged in thediscovery and development of RNA-modulating therapeutics for thetreatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne muscular dystrophy (DMD), Myotonicdystrophy and Huntington's disease.

Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients. www.prosensa.com
CONTACT: Prosensa Holding N.V.         Celia Economides, Senior Director IR & Corporate Communications         Phone: +1 917 941 9059         Email: c.economides@prosensa.nl

Prosensa Holding B.V. Logo